RESULTS: In 825,707 men, utilization of radiation therapy declined and utilization of radical prostatectomy increased for all prostate cancer risk-groups between 2004-2013 (p<0.0001). Observation for low-risk prostate cancer increased from 16.3% in 2004-2005 to 32.0% in 2012-2013 (p<0.0001). Significant treatment variation was observed based on Commission on Cancer-facility type. For all riskgroups, rates of treatment according to facility type ranged from 28.4% to 76.9% for radical prostatectomy, 3.6% to 16.2% for brachytherapy, 13.7% to 28.1% for external beam radiation therapy, 1.3% to 7.3% for androgen deprivation therapy, 4.6% to 19.1% for observation, and 0% to 2.1% for cryotherapy. The highest rates of observation for low-risk disease were observed in academic centers. After adjusting for sociodemographic and facility factors, the highest proportions of treatment variation attributable to the single institution were observed for CT (59%, 95%CI 0.45-0.73) and BT (46%, 95%CI 38-53%), while the lowest proportion of treatment variation was observed for ADT (14%, 95%CI 12-15%), and Observation (15%, 95%CI 14-17%). The results were consistent in the sensitivity analysis and in all NCCN risk-groups.
INTRODUCTION AND OBJECTIVES: Chemoprevention of prostate cancer (PCa) has been extensively investigated in the last decades. So far only 5-alpha-reductase-inhibitors (5-ARI) are supported by clinical evidence to have chemopreventive effect on PCa incidence, hence unclear in terms of prevention of aggressive PCa. Evidence for an effect of statins on PCa is conflicting. The interaction between dyslipidemia and carcinogenesis is still to be established. The aim of the study was to analyse the influence of statins intake on PSA values and PCa development.
METHODS: A population-based analysis including 4314 men from the European Randomized Study of Screening for Prostate Cancer (ERSPC) database was conducted. Data about drug intake, age, family history and symptoms was obtained by a self-administered questionnaire. A transrectal ultrasound guided prostate biopsy was performed in men with a PSA-level > 3ng/ml. Tumor stage and grade were registered, incidence and mortality data were obtained through registry linkages. PCa incidence and grade, total PSA value, free-to-total PSA and overall survival were compared between statin users and non-users, respectively. RESULTS: Over a follow-up period of 9.6 years men with statin (n¼761) exposure had insignificantly lower risk to be diagnosed with PCa ([stat+] hazard ratio (HR) 0.77, 95 % confidence interval (CI) 0.58 to 1.02. Statin users had less low risk PCa compared to non-users (p<0.05) at baseline visit while there was no difference in other PCa risk groups (according to d'Amico risk groups classification) or at follow-up visit. Interestingly, total PSA values were lower in statin users both for baseline (1.5 vs. 1.8 ng/ml, p<0.001) and follow-up-visits (after four years) (1.8 vs. 2.1ng/ml, p<0.001). Overall mortality was higher among statin users compared to non-users ([stat+] HR 1.67, 95% CI 1.36 to 2.04, however the competing risk analysis could demonstrate that PCa incidence was not influenced by overall-mortality.
CONCLUSIONS: In our study population we could demonstrate that statins intake did not alter overall PCa risk in a statistically significant manner. However, the finding of persistently lower PSA values in statin users is of potential clinical importance. It suggests that PSA cutoff values should be lowered in statin users otherwise it may introduce potential bias towards delayed PCa detection in this group, especially outside screening setting. On the other hand lower PSA values may suggest a durable protective effect of statins on PCa development.
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PD47-10 THE RESEARCH IMPLICATIONS OF PSA REGISTRY ERRORS
INTRODUCTION AND OBJECTIVES: Errors in prostate specific antigen (PSA) values included in prostate cancer registries have called into question clinical research studies that rely on this information. We sought to characterize the potential effects of PSA registry errors on clinical research by comparing cohorts based on registry PSA values with those based on laboratory values extracted from an integrated national health care system. METHODS: We defined three example cohorts of men with prostate cancer using data from the VA integrated health care system: those with 00 very low 00 (<4.0 ng/mL), 00 low 00 (<10.0 ng/mL), and 00 high 00 (20-100 ng/mL) PSA values. We compared the composition of each cohort when using the cancer registry versus the electronic health record PSA values. We compared overall survival for each cohort as an example clinical outcome. We fit multivariable proportional hazards models to determine the importance of the PSA source in each cohort.
RESULTS: There was significant discordance when using cancer registry versus electronic health record PSA values to identify a cohort of patients with 00 very low PSA 00 values. While 7,286 were included in both cohorts, one third (n¼3,515) of the cohort defined using cancer registry PSA values was misclassified and 1,800 additional patients were identified when using electronic health record data. The concordance was highest for patients with 00 low 00 PSA values, with 21,860 (98%) of patients identified in both the cancer registry and electronic health record based cohorts. Cancer registry PSA values misclassified 41% (604) of the 00 high 00 PSA cohort, and 133 additional patients were identified using electronic health record data. Comparisons of overall survival in the examples cohorts identified a difference in overall survival in the 00 very low 00 (log rank P¼0.03), but not the 00 low 00 or 00 high 00 PSA cohorts.
CONCLUSIONS: Patient cohorts based on cancer registry PSA values may have high rate of misclassification, particularly among patients with 00 very low 00 or 00 high 00 PSA values. In some cases, differences in cohorts resulted in measurable differences in overall survival. Attempts should be made to validate cancer registry PSA data to ensure accurate and reproducible results. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e899
